Participated · Seed · Nov 2025

Founded in 2024 by four former CyberArk executives, Malanta has built what it calls the world’s first AI-powered Pre-Attack Prevention platform. The product scans for early digital indicators—such as newly registered domains, command-and-control server setups and phishing kit creation—and automatically disrupts adversaries during their preparation phase. The company already holds one patent, with two more applications in process, and has secured several paying customers who use the system to neutralize threats proactively. Malanta collaborated with Israel’s National Cyber Directorate during the Swords of Iron War to help uncover vulnerabilities and dismantle hostile attack infrastructure. Headquartered in Tel Aviv, the 20-person team combines deep expertise in offensive and defensive cybersecurity, artificial intelligence and large-scale enterprise product development. While specific revenue figures are not disclosed, the presence of paying customers signals early commercial traction. The fresh capital will be used to accelerate product development, expand go-to-market efforts and scale headcount.

Participated · Series A · Mar 2025

brain.space builds a Brain-Data-as-a-Service ecosystem aimed at exclusive generative AI mental modeling and the development of large mental models (LMMs). Its core product offering includes the Brain Sensei Headset, a non-invasive, operable device with 115 dry EEG sensors that requires a roughly 3-minute setup and minimal training. The Brain Sensei operates autonomously and can integrate additional physiological sensors such as eye trackers, ECG and GSR to collect high-resolution brain data and assess mental and cognitive states. Led by CEO Yair Levy, the company positions its platform to standardize brain data for integration with machine learning and human intelligence. Financially, brain.space completed a funding package that includes an $11M Series A and a $3.5M non-dilutive grant from the Israel Innovation Authority. The company intends to use the proceeds to further work on standardized brain data and the development of LMMs. brain.space develops a wireless, user-friendly EEG helmet with 460 sensors designed for automated, gel-free setup and higher-density recordings than traditional EEG systems. The company pairs the headset with a comprehensive software end-to-end stack intended to make brain activity easy to integrate into applications. It has been in development for four years and is just emerging from stealth, with no peer-reviewed documentation yet but initial research collaborations underway with Ben Gurion University’s Department of Cognitive and Brain Science and a medical center in Israel. Target use cases the company is exploring include tracking learning disabilities, markers of cognitive decline such as Alzheimer’s, athletic performance, and telehealth monitoring. Brain.space is also demonstrating the device in space as part of the Axiom-1 mission to collect longitudinal neural data aboard the ISS. The company says headset pricing will vary by application and likely sit between consumer bargain systems and research-grade rigs, though it declined to provide exact figures.

Participated · Equity · Oct 2024

FeelBetter has developed an AI-based Pharmaco-Clinical Intelligence platform with four core tools: Insight (risk stratification), Navigator (workflow management), Action (AI decision-support for pharmacists) and Impact (post-intervention monitoring). The company reports reaching more than 300,000 patients daily and cites partnerships with Leumit HMO, Atlantic Health, and a retrospective study at Brigham & Women’s Hospital validating its outcomes. Published and partner-reported results include large reductions in hospital admissions and days, clinical improvements in LDL and HbA1c, a 5x increase in pharmacist capacity reported by Leumit, and estimated cost savings per high-risk patient. FeelBetter has raised $11.5 million from grants and investors to date and is actively seeking Series A funding. The firm says it is expanding its global footprint and plans to partner with more U.S.-based health systems to pursue broader adoption of its population- and individual-level solution.

Participated · Seed · Feb 2024

Sibli builds AI-driven investment research technology that leverages advancements in natural language processing and generative AI to process vast amounts of unstructured data and surface relevant insights. Its platform is designed for use by fundamental and quantitative asset managers to secure an information advantage and improve decision-making, efficiency, and performance. The technology was developed with academic roots and is marketed to top-tier asset managers, including several in the Maple 8. Led by CEO Alik Sokolov, the company says some clients have launched novel strategies enabled by its generative-AI capabilities. Sibli intends to use the newly raised capital to accelerate growth and further develop its technology.

Participated · Equity · Aug 2023

FeelBetter offers a SaaS-based Pharmaco-Clinical Intelligence platform that synthesizes and analyzes healthcare data from multiple sources to pinpoint patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management. The platform proactively suggests immediate, actionable interventions to reduce polypharmacy risks. It also aids healthcare providers in monitoring patients’ progress and measuring the impact of clinical interventions. By using FeelBetter, provider organizations can allocate resources to serve patients and minimize preventable, costly use of healthcare services. The company is led by CEO and co-founder Liat Primor and CTO/COO and co-founder Yoram Hordan, and is based in Boston, MA and Tel Aviv, Israel. Financially, the company raised $5.9M in the latest round, bringing total funding to $8M.